Amgen’s Rebate Bundling Makes It ‘Economically Unfeasible’ For Regeneron To Sell Praluent
Executive Summary
Regeneron antitrust suit alleges Amgen’s bundling of Repatha rebates with Otezla and Enbrel has restricted Praluent’s market access and ability to compete with Repatha.
You may also be interested in...
Amgen Aims To Stay Regeneron Antitrust Suit Based On Possible Supreme Court Action
Amgen says contracts it submitted to district court show Otezla rebates were not conditioned on customers covering its cholesterol-lowering drug Repatha instead of Regeneron’s Praluent. It requests stay of the litigation until Supreme Court acts on Amgen’s cert petition on the patent case between the two competitors.
Pharma Mergers: FTC Should Consider Monitoring R&D, Assessing PBM Contracts, Experts Advise
Panelists at FTC/DOJ workshop suggest new remedies to ensure pharma mergers are not anti-competitive. The commission should support scientists and ensure R&D continues, one expert says.
Supreme Court May Consider Ruling Invalidating Amgen’s Repatha Patents
Court asks Solicitor General to weigh in on petition challenging Federal Circuit’s standard for determining patent enablement in Amgen’s dispute with PCSK9 inhibitor rivals Sanofi and Regeneron. GlaxoSmithKline, Biogen, Bristol-Myers Squibb, and Merck filed briefs in support of Amgen.